{
    "abstract": "Background Nearly all of the 500,000 new cases of cervical cancer and 270,000 deaths occur in middle or lower income countries. Yet the two most prevalent HPV vaccines are unaffordable to most. Even prices to Gavi, the Vaccine Alliance, are unaffordable to graduating countries, once they lose Gavi subsidies. Merck and Glaxosmithkline (GSK) claim their prices to Gavi equal their manufacturing costs; but these costs remain undisclosed. We undertook this investigation to estimate those costs. Methods Searches in published and commercial literature for information about the manufacturing of these vaccines. Interviews with experts in vaccine manufacturing. Findings This detailed sensitivity analysis, based on the best available evidence, finds that after a first set of batches for affluent markets, manufacturing costs of Gardasil for developing countries range between $0.48 and $0.59 a dose, a fraction of its alleged costs of $4.50. Because volume of Cervarix is low, its per unit costs are much higher, though at comparable volumes, its costs would be similar. Interpretation Given the recovery of fixed and annual costs from sales in affluent markets, Merck's break-even price to Gavi could be $0.50\u2013$0.60, not $4.50. These savings could support Gavi programs to strengthen delivery and increase coverage. Outside Gavi, prices to lower- and middle-income countries, with profit, could also be lowered and made available to millions more adolescents at risk. These estimates and their policy implications deserve further discussion.",
    "author_highlights": [
        {
            "endOffset": 11300,
            "sentence": "This is one of the few original investigations of vaccine manufacturing and costs.",
            "startOffset": 11218
        },
        {
            "endOffset": 11386,
            "sentence": "Manufacturing costs of Gardasil-4 are much lower than the \u201cno profits\u201d price to Gavi.",
            "startOffset": 11301
        },
        {
            "endOffset": 11457,
            "sentence": "Lower sales make per-unit costs of Cervarix much higher than Gardasil.",
            "startOffset": 11387
        },
        {
            "endOffset": 11536,
            "sentence": "This study may have relevance to the costs and fair pricing of other vaccines.",
            "startOffset": 11458
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "de Sanjos\u00e9"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Serrano"
                },
                {
                    "first": "X.",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Brotons"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Bruni"
                },
                {
                    "first": "F. X.",
                    "initial": "F.X.",
                    "last": "Bosch"
                }
            ],
            "firstpage": "D1",
            "issn": "18732518",
            "lastpage": "83",
            "pmid": "23510764",
            "pub_year": 2012,
            "title": "Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report.",
            "volume": "30"
        },
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Arbyn"
                },
                {
                    "first": "X.",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "de sanjos\u00e9"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Bruni"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Saraiya"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Bray"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Ferlay"
                }
            ],
            "doi": "10.1093/annonc/mdr015",
            "firstpage": "2675",
            "issn": "09237534",
            "lastpage": "2686",
            "pmid": "21471563",
            "pub_year": 2011,
            "title": "Worldwide burden of cervical cancer in 2008",
            "volume": "22"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Saman",
                    "initial": "S.",
                    "last": "Warnakulasuriya"
                }
            ],
            "doi": "10.1016/j.oraloncology.2008.06.002",
            "firstpage": "309",
            "issn": "13688375",
            "lastpage": "316",
            "pmid": "18804401",
            "pub_year": 2009,
            "title": "Global epidemiology of oral and oropharyngeal cancer",
            "volume": "45"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Erich M.",
                    "initial": "E.M.",
                    "last": "Sturgis"
                },
                {
                    "first": "K. Kian",
                    "initial": "K.K.",
                    "last": "Ang"
                }
            ],
            "doi": "10.6004/jnccn.2011.0055",
            "firstpage": "665",
            "issn": "15401405",
            "lastpage": "673",
            "pmid": "21636538",
            "pub_year": 2011,
            "title": "The epidemic of HVP-associated oropharyngeal cancer is here: Is it time to change our treatment paradigms?",
            "volume": "9"
        },
        "b0030": {
            "authors": [
                {
                    "first": "John T.",
                    "initial": "J.T.",
                    "last": "Schiller"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Garland"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.04.108",
            "firstpage": "F123",
            "issn": "0264410X",
            "lastpage": "F138",
            "pub_year": 2012,
            "title": "A review of clinical trials of human papillomavirus prophylactic vaccines",
            "volume": "30"
        },
        "b0035": null,
        "b0040": {
            "authors": [
                {
                    "first": "Beibei",
                    "initial": "B.",
                    "last": "Lu"
                },
                {
                    "first": "Ambuj",
                    "initial": "A.",
                    "last": "Kumar"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Anna R.",
                    "initial": "A.R.",
                    "last": "Giuliano"
                }
            ],
            "doi": "10.1186/1471-2334-11-13",
            "issn": "14712334",
            "pmid": "21226933",
            "pub_year": 2011,
            "title": "Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis",
            "volume": "11"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Georges",
                    "initial": "G.",
                    "last": "Van Kriekinge"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Cibula"
                },
                {
                    "first": "Nadia",
                    "initial": "N.",
                    "last": "Demarteau"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.11.049",
            "firstpage": "733",
            "issn": "0264410X",
            "lastpage": "739",
            "pmid": "24291200",
            "pub_year": 2014,
            "title": "Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths",
            "volume": "32"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Bradley",
                    "initial": "B.",
                    "last": "Fox"
                },
                {
                    "first": "Sofia",
                    "initial": "S.",
                    "last": "Scholar"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Rosen"
                },
                {
                    "first": "Nahida",
                    "initial": "N.",
                    "last": "Chakhtoura"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Lebacq"
                },
                {
                    "first": "Robbert",
                    "initial": "R.",
                    "last": "Van Der Most"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Sandra L.",
                    "initial": "S.L.",
                    "last": "Giannini"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "Sanjoy K.",
                    "initial": "S.K.",
                    "last": "Datta"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                }
            ],
            "doi": "10.4161/hv.7.12.18282",
            "firstpage": "1359",
            "issn": "15548600",
            "lastpage": "1373",
            "pmid": "22048172",
            "pub_year": 2011,
            "title": "Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years",
            "volume": "7"
        },
        "b0055": null,
        "b0060": null,
        "b0065": {
            "authors": [
                {
                    "first": "Prianka",
                    "initial": "P.",
                    "last": "Mukhopadhyay"
                },
                {
                    "first": "Bhaskar",
                    "initial": "B.",
                    "last": "Paul"
                }
            ],
            "doi": "10.4103/0970-0218.58407",
            "firstpage": "370",
            "issn": "09700218",
            "lastpage": "371",
            "pub_year": 2009,
            "title": "Introducing HPV vaccine in developing countries - Addressing the challenge",
            "volume": "34"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Jan M.",
                    "initial": "J.M.",
                    "last": "Agosti"
                },
                {
                    "first": "Sue J.",
                    "initial": "S.J.",
                    "last": "Goldie"
                }
            ],
            "doi": "10.1056/NEJMp078053",
            "firstpage": "1908",
            "issn": "00284793",
            "lastpage": "1910",
            "pmid": "17494923",
            "pub_year": 2007,
            "title": "Introducing HPV vaccine in developing countries - Key challenges and issues",
            "volume": "356"
        },
        "b0075": null,
        "b0080": null,
        "b0085": {
            "authors": [
                {
                    "first": "R. T.",
                    "initial": "R.T.",
                    "last": "Mahoney"
                },
                {
                    "first": "D. P.",
                    "initial": "D.P.",
                    "last": "Francis"
                },
                {
                    "first": "N. M.",
                    "initial": "N.M.",
                    "last": "Frazatti-Gallina"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Precioso"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Raw"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Watler"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Whitehead"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Whitehead"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.02.064",
            "firstpage": "4892",
            "issn": "0264410X",
            "lastpage": "4896",
            "pmid": "22406455",
            "pub_year": 2012,
            "title": "Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil",
            "volume": "30"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Richard T.",
                    "initial": "R.T.",
                    "last": "Mahoney"
                }
            ],
            "doi": "10.1016/0264-410X(90)90101-Q",
            "firstpage": "397",
            "issn": "0264410X",
            "lastpage": "401",
            "pmid": "2144390",
            "pub_year": 1990,
            "title": "Cost of plasma-derived hepatitis B vaccine production",
            "volume": "8"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Smith"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lipsitch"
                },
                {
                    "first": "Jeffrey W.",
                    "initial": "J.W.",
                    "last": "Almond"
                }
            ],
            "doi": "10.1016/S0140-6736(11)60478-9",
            "firstpage": "428",
            "issn": "01406736",
            "lastpage": "438",
            "pmid": "21664680",
            "pub_year": 2011,
            "title": "Vaccine production, distribution, access, and uptake",
            "volume": "378"
        },
        "b0100": null,
        "b0105": null,
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "Donald W.",
                    "initial": "D.W.",
                    "last": "Light"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Warburton"
                }
            ],
            "doi": "10.1057/biosoc.2010.40",
            "firstpage": "34",
            "issn": "17458552",
            "lastpage": "50",
            "pub_year": 2011,
            "title": "Demythologizing the high costs of pharmaceutical research",
            "volume": "6"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Sara E.",
                    "initial": "S.E.",
                    "last": "Crager"
                },
                {
                    "first": "Ethan",
                    "initial": "E.",
                    "last": "Guillen"
                },
                {
                    "first": "Matt",
                    "initial": "M.",
                    "last": "Price"
                }
            ],
            "doi": "10.1177/009885880903500202",
            "firstpage": "253",
            "issn": "00988588",
            "lastpage": "279",
            "pmid": "19697749",
            "pub_year": 2009,
            "title": "University contributions to the HPV vaccine and implications for access to vaccines in developing countries: Addressing materials and know-how in university technology transfer policy",
            "volume": "35"
        },
        "b0125": null,
        "b0130": null,
        "b0135": null,
        "b0140": null,
        "b0145": null,
        "b0150": {
            "authors": [
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Jit"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Brisson"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "Portnoy"
                },
                {
                    "first": "Raymond",
                    "initial": "R.",
                    "last": "Hutubessy"
                }
            ],
            "doi": "10.1016/S2214-109X(14)70237-2",
            "firstpage": "e406",
            "issn": "2214109X",
            "lastpage": "e414",
            "pmid": "25103394",
            "pub_year": 2014,
            "title": "Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study",
            "volume": "2"
        }
    },
    "body_text": [
        {
            "endOffset": 22463,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "For the analysis, we used the average of these estimated annual costs for a middle estimate, $9.0 million for Gardasil-4 and $7.2 for Cervarix.",
            "startOffset": 22320,
            "title": "Manufacturing personnel"
        },
        {
            "endOffset": 29219,
            "parents": [],
            "secId": "s0055",
            "sentence": "While it is based on the best available information, the lack of access to verifiable manufacturing information from the companies has prevented more accurate figures.",
            "startOffset": 29052,
            "title": "Limitations"
        },
        {
            "endOffset": 18276,
            "parents": [],
            "secId": "s0010",
            "sentence": "Brief summaries of the major categories of expense are given here.",
            "startOffset": 18210,
            "title": "Methods"
        },
        {
            "endOffset": 25705,
            "parents": [],
            "secId": "s0050",
            "sentence": "For this study, an analysis of sales, volume and profits was carried out and is reported in Appendix B.",
            "startOffset": 25602,
            "title": "Discussion"
        },
        {
            "endOffset": 22832,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For Cervarix, the cost estimates are $3.21, $3.69, and $4.59 million.",
            "startOffset": 22763,
            "title": "Factory and administrative overheads"
        },
        {
            "endOffset": 24127,
            "parents": [],
            "secId": "s0045",
            "sentence": "Fig. 1 shows the average costs per dose of the first and second sets from Tables 1 and 2.",
            "startOffset": 24038,
            "title": "Results"
        },
        {
            "endOffset": 15317,
            "parents": [],
            "secId": "s0005",
            "sentence": "Negotiated prices to third parties are usually undisclosed.",
            "startOffset": 15258,
            "title": "Introduction"
        },
        {
            "endOffset": 31218,
            "parents": [],
            "secId": "s0075",
            "sentence": "Salary support from Rowan University.",
            "startOffset": 31181,
            "title": "Funding"
        },
        {
            "endOffset": 13724,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 13723,
                    "startOffset": 13718
                },
                "b0025": {
                    "endOffset": 13723,
                    "startOffset": 13718
                }
            },
            "secId": "s0005",
            "sentence": "While infection with most strains of HPV are transient and benign, 16 HPV strains are linked to cancerous and precancerous lesions in the genital and oral areas [4,5].",
            "startOffset": 13557,
            "title": "Introduction"
        },
        {
            "endOffset": 19798,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Thus the low, middle, and high annualized capital costs to replace all buildings and equipment associated with manufacturing Gardasil-4 are $12.9 million, $17.2 million, and $21.5 million respectively.",
            "startOffset": 19597,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 26803,
            "parents": [],
            "secId": "s0050",
            "sentence": "Thus, even with only two companies, lively price competition could take place.",
            "startOffset": 26725,
            "title": "Discussion"
        },
        {
            "endOffset": 15832,
            "parents": [],
            "secId": "s0005",
            "sentence": "As we expand volumes, the cost per unit can go down.",
            "startOffset": 15780,
            "title": "Introduction"
        },
        {
            "endOffset": 19341,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For Gardasil, one quarter of the $1 billion spent by Merck in building its manufacturing complex in Durham, NC was used as the high estimate; a 20% discount, or $200 million for the middle estimate; and a 40% discount, or $150 million for the low estimate.",
            "startOffset": 19085,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 30697,
            "parents": [],
            "secId": "s0065",
            "sentence": "YZ has received no payments from pharmaceutical companies and declares no conflicts of interest.",
            "startOffset": 30601,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 24621,
            "parents": [],
            "secId": "s0045",
            "sentence": "For Cervarix, the estimated manufacturing costs in the first set of 3.6 million doses ranges from $6.16 to $9.39 a dose in single-dose vials.",
            "startOffset": 24480,
            "title": "Results"
        },
        {
            "endOffset": 20191,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "As explained in Appendix A, the yield for Gardasil-4 is estimated to be 29 mg/L, and for Cervarix 40 mg/L.",
            "startOffset": 20085,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 22762,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Sensitivity analysis puts Gardasil-4\u2019s low, middle, and high costs at $4.39, $5.12, and $6.38 million.",
            "startOffset": 22660,
            "title": "Factory and administrative overheads"
        },
        {
            "endOffset": 30503,
            "parents": [],
            "secId": "s0065",
            "sentence": "CC received $1700 from MSF through Rowan University for this research.",
            "startOffset": 30433,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 15257,
            "parents": [],
            "secId": "s0005",
            "sentence": "As the first vaccines against HPV-related cancers, the retail prices for Gardasil-4 and Cervarix were high, at US$150\u2013$190 per dose.",
            "startOffset": 15125,
            "title": "Introduction"
        },
        {
            "endOffset": 14601,
            "parents": [],
            "secId": "s0005",
            "sentence": "Cervarix consists of two virus-like particles derived from HPV types 16 and 18.",
            "startOffset": 14522,
            "title": "Introduction"
        },
        {
            "endOffset": 20385,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 20384,
                    "startOffset": 20380
                }
            },
            "secId": "s0020",
            "sentence": "The Gardasil-4 vaccine consists of a 0.5 mL vial containing 20 \u00c2\u03bcg each of HPV-6 L1 and HPV-18 L1 virus-like particles (VLPs) protein, and 40 \u00c2\u03bcg each of HPV-11 and HPV-16 L1 VLPs protein [21].",
            "startOffset": 20192,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 27108,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 27107,
                    "startOffset": 27103
                }
            },
            "secId": "s0050",
            "sentence": "Gavi\u2019s leadership has been criticized for not investigating real manufacturing costs and bargaining for lower prices that would be sustainable for its countries [26].",
            "startOffset": 26942,
            "title": "Discussion"
        },
        {
            "endOffset": 29997,
            "parents": [],
            "secId": "s0060",
            "sentence": "YZ researched and drafted the Introduction, and contributed to all aspects of the paper and calculations.",
            "startOffset": 29892,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 30601,
            "parents": [],
            "secId": "s0065",
            "sentence": "She has received no payments from pharmaceutical companies and declares no conflicts of interest.",
            "startOffset": 30504,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 16835,
            "parents": [],
            "secId": "s0010",
            "sentence": "We searched the published, grey, commercial, and company literature for information pertinent to the manufacturing and costs of these vaccines.",
            "startOffset": 16692,
            "title": "Methods"
        },
        {
            "endOffset": 19942,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The low, middle, and high annualized capital costs for manufacturing Cervarix are $10.7 million, $14.3 million, and $17.9 million respectively.",
            "startOffset": 19799,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 24777,
            "parents": [],
            "secId": "s0045",
            "sentence": "Table 3 indicates that the average costs per single dose in the second set produced within a fiscal year would drop to US$0.62\u2013$0.82 for single-fill vials.",
            "startOffset": 24622,
            "title": "Results"
        },
        {
            "endOffset": 28292,
            "parents": [],
            "secId": "s0050",
            "sentence": "Merck and GSK have discount and charitable programs that increase access to their HPV vaccines for some countries.",
            "startOffset": 28178,
            "title": "Discussion"
        },
        {
            "endOffset": 26942,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 26941,
                    "startOffset": 26937
                }
            },
            "secId": "s0050",
            "sentence": "This would make HPV vaccines more accessible, as happened when competition lowered prices for the first generation of HIV-AIDS drugs [25].",
            "startOffset": 26804,
            "title": "Discussion"
        },
        {
            "endOffset": 17796,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 17795,
                    "startOffset": 17788
                },
                "b0090": {
                    "endOffset": 17795,
                    "startOffset": 17788
                },
                "b0095": {
                    "endOffset": 17795,
                    "startOffset": 17788
                }
            },
            "secId": "s0010",
            "sentence": "In accordance with standard accounting practices for estimating costs of manufacturing, other costs are not included such as research and development (R&D), marketing, or general administration and legal services [17\u201319].",
            "startOffset": 17575,
            "title": "Methods"
        },
        {
            "endOffset": 20701,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 20700,
                    "startOffset": 20696
                }
            },
            "secId": "s0020",
            "sentence": "Cervarix, 0.5 mL vial, contains 20 \u00c2\u03bcg each of HPV-16 and HPV-18 L1 VLP proteins [22].",
            "startOffset": 20615,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 26503,
            "parents": [],
            "secId": "s0050",
            "sentence": "Appendix B shows that from 2006 to 2015, GSK received gross revenues of about US$2.9 billion from Cervarix sales.",
            "startOffset": 26390,
            "title": "Discussion"
        },
        {
            "endOffset": 23361,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "There is no indication that the discounts for these vials themselves are substantial.",
            "startOffset": 23276,
            "title": "Filling and packaging"
        },
        {
            "endOffset": 28177,
            "parents": [],
            "secId": "s0050",
            "sentence": "Setting low vaccine prices for Gavi-eligible countries is an important moral commitment by the companies to reduce global health inequities by preventing cancer and deaths in lower-income countries.",
            "startOffset": 27979,
            "title": "Discussion"
        },
        {
            "endOffset": 24825,
            "parents": [],
            "secId": "s0045",
            "sentence": "Ten-dose vials would cost $0.24\u2013$0.32 per dose.",
            "startOffset": 24778,
            "title": "Results"
        },
        {
            "endOffset": 27800,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 27799,
                    "startOffset": 27796
                }
            },
            "secId": "s0050",
            "sentence": "In the 33 countries where HPV vaccines are likely to have the greatest benefit, only 4 had introduced national vaccination programs as of January 2012 [2].",
            "startOffset": 27645,
            "title": "Discussion"
        },
        {
            "endOffset": 27485,
            "parents": [],
            "secId": "s0050",
            "sentence": "A price at manufacturing cost would greatly increase Gavi\u2019s capacity to vaccinate more children.",
            "startOffset": 27389,
            "title": "Discussion"
        },
        {
            "endOffset": 17257,
            "parents": [],
            "secId": "s0010",
            "sentence": "We gained insights from corresponding and interviewing some of them.",
            "startOffset": 17189,
            "title": "Methods"
        },
        {
            "endOffset": 28404,
            "parents": [],
            "secId": "s0050",
            "sentence": "Both companies rank high in the global Access to Medicines Index: GSK ranks first and Merck sixth in the world.",
            "startOffset": 28293,
            "title": "Discussion"
        },
        {
            "endOffset": 14100,
            "parents": [],
            "secId": "s0005",
            "sentence": "The quadrivalent HPV recombinant vaccine called Gardasil-4 and the bivalent HPV vaccine called Cervarix were developed by Merck and GlaxoSmithKline (GSK) respectively.",
            "startOffset": 13933,
            "title": "Introduction"
        },
        {
            "endOffset": 14521,
            "parents": [],
            "secId": "s0005",
            "sentence": "Gardasil-4 consists of four virus-like particles derived from HPV types 6, 11, 16 and 18.",
            "startOffset": 14432,
            "title": "Introduction"
        },
        {
            "endOffset": 17070,
            "parents": [],
            "secId": "s0010",
            "sentence": "Company reports and past press releases were also helpful.",
            "startOffset": 17012,
            "title": "Methods"
        },
        {
            "endOffset": 27388,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 27239,
                    "startOffset": 27235
                },
                "b0140": {
                    "endOffset": 27387,
                    "startOffset": 27380
                },
                "b0145": {
                    "endOffset": 27387,
                    "startOffset": 27380
                }
            },
            "secId": "s0050",
            "sentence": "While Gavi emphasizes vaccine introductions [27], it appears to be meeting little of the overall demand from member countries, which is estimated to rise to 39 million doses a year by 2020 [28,29].",
            "startOffset": 27191,
            "title": "Discussion"
        },
        {
            "endOffset": 16220,
            "parents": [],
            "secId": "s0005",
            "sentence": "Since neither manufacturer provided evidence of its cost of goods, this study was undertaken to determine what they are and how they vary by volume.",
            "startOffset": 16072,
            "title": "Introduction"
        },
        {
            "endOffset": 23619,
            "parents": [],
            "secId": "s0045",
            "sentence": "As Table 1 shows, the estimated manufacturing cost for Gardasil-4 ranges from US$2.07 to $3.05 per dose.",
            "startOffset": 23515,
            "title": "Results"
        },
        {
            "endOffset": 19084,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For sensitivity analysis, as described in Appendix A, capital costs were estimated based on the share of the total manufacturing complex used for Gardasil or Cervarix, at most one quarter of the total complex cost.",
            "startOffset": 18870,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 13867,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 13866,
                    "startOffset": 13861
                },
                "b0035": {
                    "endOffset": 13866,
                    "startOffset": 13861
                }
            },
            "secId": "s0005",
            "sentence": "HPV-16 and -18 are associated with 70% of invasive cervical cancers worldwide, as well as cancer of the vulva, vagina, anus, and throat [6,7].",
            "startOffset": 13725,
            "title": "Introduction"
        },
        {
            "endOffset": 25455,
            "parents": [],
            "secId": "s0050",
            "sentence": "For the first set of 15.4 million doses of Gardasil-4, manufacturing costs lie between US$2.07 and $3.05.",
            "startOffset": 25350,
            "title": "Discussion"
        },
        {
            "endOffset": 14432,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although Merck has subsequently developed Gardasil-9, Gardasil-4 and Cervarix remain widely used and are supplied by contract to Gavi, the Vaccine Alliance (Gavi), a public private partnership that provides financial subsidies to accelerate the introduction of new and under-utilized vaccines in the poorest countries of the world.",
            "startOffset": 14101,
            "title": "Introduction"
        },
        {
            "endOffset": 31505,
            "parents": [],
            "secId": "s0080",
            "sentence": "It could be affordably priced, with profits, for millions of patients in countries where most cases occur.",
            "startOffset": 31399,
            "title": "Possible summary"
        },
        {
            "endOffset": 17011,
            "parents": [],
            "secId": "s0010",
            "sentence": "We used Scopus, Web of Science, PubMed, Proquest, Factiva and Bloomberg, using various combinations of these search terms: vaccine, production, manufacturing, cost, and costs.",
            "startOffset": 16836,
            "title": "Methods"
        },
        {
            "endOffset": 31101,
            "parents": [],
            "secId": "s0070",
            "sentence": "Rowan staff played no role in the study.",
            "startOffset": 31061,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 18354,
            "parents": [],
            "secId": "s0010",
            "sentence": "See Appendix A (details on manufacturing cost estimates) for further details.",
            "startOffset": 18277,
            "title": "Methods"
        },
        {
            "endOffset": 20084,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The number of doses that can be made from a given batch produced with the raw materials and equipment critically affects cost.",
            "startOffset": 19958,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 28737,
            "parents": [],
            "secId": "s0050",
            "sentence": "For countries just above the threshold income for Gavi subsidies, the lowest world prices of $12\u201313 per dose are much higher than what scores of those countries can afford.",
            "startOffset": 28565,
            "title": "Discussion"
        },
        {
            "endOffset": 22256,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "They are paid on annual salaries, and we estimate the costs of personnel for Gardasil-4 to range between $7.99 and $11.22 million a year and for Cervarix between $6.37 and $8.95 million.",
            "startOffset": 22070,
            "title": "Manufacturing personnel"
        },
        {
            "endOffset": 21331,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For Cervarix, the high estimate for materials for 3.6 million doses is approximately $1.27 million.",
            "startOffset": 21232,
            "title": "Raw materials"
        },
        {
            "endOffset": 17574,
            "parents": [],
            "secId": "s0010",
            "sentence": "Costs fall into four categories: fixed annualized capital costs of building, pipes, equipment, and Good Manufacturing Practices (GMP) qualifications; two kinds of variable costs, annual costs for labor and per-batch costs for raw materials and filling and packaging the vials; and factory overheads (indirect costs).",
            "startOffset": 17258,
            "title": "Methods"
        },
        {
            "endOffset": 29001,
            "parents": [],
            "secId": "s0050",
            "sentence": "This study challenges the manufacturers and Gavi to commence vigorous discussion about how to achieve such prices now and lower prices in the future.",
            "startOffset": 28852,
            "title": "Discussion"
        },
        {
            "endOffset": 16071,
            "parents": [],
            "secId": "s0005",
            "sentence": "GSK made similar statements and offered Cervarix for $4.60 a dose.",
            "startOffset": 16005,
            "title": "Introduction"
        },
        {
            "endOffset": 29730,
            "parents": [],
            "secId": "s0055",
            "sentence": "This analysis is limited to the two HPV vaccines used by Gavi, and much work is underway to develop cheaper HPV vaccines that are better suited to the realities of vaccination in developing countries.",
            "startOffset": 29530,
            "title": "Limitations"
        },
        {
            "endOffset": 18209,
            "parents": [],
            "secId": "s0010",
            "sentence": "R&D costs after a product is approved reflect investment decisions on using profits from sales to improve, upgrade, extend, or expand on that product for further sales.",
            "startOffset": 18041,
            "title": "Methods"
        },
        {
            "endOffset": 19596,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For Cervarix, one quarter of the $830 million spent by GSK in building its manufacturing complex in France was used as the high estimate; a 20% discount, or $166 million for the middle estimate; and a 40% discount, or $124.5 million for the low estimate.",
            "startOffset": 19342,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 23514,
            "parents": [],
            "secId": "s0045",
            "sentence": "The estimated low, middle, and high costs of manufacturing per dose is the sum of the total cost divided by volume of doses within a fiscal year.",
            "startOffset": 23369,
            "title": "Results"
        },
        {
            "endOffset": 15779,
            "parents": [],
            "secId": "s0005",
            "sentence": "In 2013, Merck offered to sell Gardasil to Gavi for US$4.50, and the President of Merck Vaccines said, \u201cThe price is what we calculate to be our cost of goods.",
            "startOffset": 15620,
            "title": "Introduction"
        },
        {
            "endOffset": 23805,
            "parents": [],
            "secId": "s0045",
            "sentence": "Manufacturing a second set of 15.4 million doses within a year costs $0.48\u2013$0.59 per dose because fixed capital costs and annual personnel costs are included in the first set (Table 2).",
            "startOffset": 23620,
            "title": "Results"
        },
        {
            "endOffset": 15914,
            "parents": [],
            "secId": "s0005",
            "sentence": "Our intent is to sell it to Gavi at a price that does not bring profit to Merck.\u201d",
            "startOffset": 15833,
            "title": "Introduction"
        },
        {
            "endOffset": 13556,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 13555,
                    "startOffset": 13552
                }
            },
            "secId": "s0005",
            "sentence": "Human papillomavirus (HPV) infection is linked to >99% of cervical cancers [3].",
            "startOffset": 13477,
            "title": "Introduction"
        },
        {
            "endOffset": 13932,
            "parents": [],
            "secId": "s0005",
            "sentence": "Two vaccines were developed to prevent HPV-16/18 related cancers.",
            "startOffset": 13867,
            "title": "Introduction"
        },
        {
            "endOffset": 29821,
            "parents": [],
            "secId": "s0060",
            "sentence": "DWL conceived the project, oversaw it, and co-authored the main text.",
            "startOffset": 29752,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 16004,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 16003,
                    "startOffset": 15999
                }
            },
            "secId": "s0005",
            "sentence": "She made it clear that manufacturing costs do not include research and other costs. [16].",
            "startOffset": 15915,
            "title": "Introduction"
        },
        {
            "endOffset": 18870,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 18869,
                    "startOffset": 18865
                }
            },
            "secId": "s0015",
            "sentence": "Annualized capital costs assume a 5% real (no-inflation) discount rate, 10 years of useful life for the equipment, and 25 years of useful life for the building [17].",
            "startOffset": 18705,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 29891,
            "parents": [],
            "secId": "s0060",
            "sentence": "CC researched the costs and co-authored the main text and Appendix A.",
            "startOffset": 29822,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 31180,
            "parents": [],
            "secId": "s0075",
            "sentence": "Partial funding from M\u00e9decins Sans Fronti\u00e8res (MSF) to Rowan University.",
            "startOffset": 31108,
            "title": "Funding"
        },
        {
            "endOffset": 31275,
            "parents": [],
            "secId": "s0075",
            "sentence": "In-kind library and IT support from Princeton and Rowan.",
            "startOffset": 31219,
            "title": "Funding"
        },
        {
            "endOffset": 21475,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For our sensitivity analysis, we again assumed that large buyers negotiate discounts of 20\u201340% and used these for the middle and low estimates.",
            "startOffset": 21332,
            "title": "Raw materials"
        },
        {
            "endOffset": 27190,
            "parents": [],
            "secId": "s0050",
            "sentence": "In our view, Gavi and Merck leaders need to re-price Gardasil-4 at $0.59 or less.",
            "startOffset": 27109,
            "title": "Discussion"
        },
        {
            "endOffset": 25349,
            "parents": [],
            "secId": "s0050",
            "sentence": "Based on the best available information from public sources, company reports, and interviews with experts, this study uses sensitivity ranges to estimate the manufacturing costs of Gardasil-4 and Cervarix.",
            "startOffset": 25144,
            "title": "Discussion"
        },
        {
            "endOffset": 18578,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Annualized capital costs estimate the cost of replacing manufacturing facilities, which include buildings, pipes, equipment, lines and GMP (Good Manufacturing Practices) up to beginning production.",
            "startOffset": 18381,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 16684,
            "parents": [],
            "secId": "s0005",
            "sentence": "Its limitations underscore the need for greater transparency in vaccine pricing.",
            "startOffset": 16604,
            "title": "Introduction"
        },
        {
            "endOffset": 28440,
            "parents": [],
            "secId": "s0050",
            "sentence": "Both are strong supporters of Gavi.",
            "startOffset": 28405,
            "title": "Discussion"
        },
        {
            "endOffset": 25030,
            "parents": [],
            "secId": "s0045",
            "sentence": "As shown in Appendix B, GSK appears to have sold about 2.1 million doses in 2015, substantially fewer than one set.",
            "startOffset": 24915,
            "title": "Results"
        },
        {
            "endOffset": 25760,
            "parents": [],
            "secId": "s0050",
            "sentence": "Merck has enjoyed substantial sales and gross profits.",
            "startOffset": 25706,
            "title": "Discussion"
        },
        {
            "endOffset": 24914,
            "parents": [],
            "secId": "s0045",
            "sentence": "Fig. 3 shows the average costs per dose of the first and second sets from Tables 3 and 4.",
            "startOffset": 24825,
            "title": "Results"
        },
        {
            "endOffset": 15559,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 15558,
                    "startOffset": 15551
                },
                "b0070": {
                    "endOffset": 15558,
                    "startOffset": 15551
                },
                "b0075": {
                    "endOffset": 15558,
                    "startOffset": 15551
                }
            },
            "secId": "s0005",
            "sentence": "Although these vaccines have been licensed in over 100 countries, several factors have contributed to low uptake [13\u201315].",
            "startOffset": 15438,
            "title": "Introduction"
        },
        {
            "endOffset": 23186,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "According to confidential interviews with experts on manufacturing, the wholesale unit cost of the vial, cap, and stopper for single-dose packaging is $0.21 per dose plus $0.10 for secondary packaging materials, for a total of $4.77 million for 15.4 million doses of Gardasil-4 and $1.12 million for 3.6 million doses of Cervarix.",
            "startOffset": 22856,
            "title": "Filling and packaging"
        },
        {
            "endOffset": 20493,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Thus two \u201cbatches\u201d of 11 and 16 must be manufactured to match up with the yield from one batch of 6 and 18.",
            "startOffset": 20386,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 25133,
            "parents": [],
            "secId": "s0045",
            "sentence": "If first-set costs were attributed to just this volume, the per-unit cost would jump to $10.56\u2013$16.10.",
            "startOffset": 25031,
            "title": "Results"
        },
        {
            "endOffset": 24343,
            "parents": [],
            "secId": "s0045",
            "sentence": "This is illustrated in Fig. 2.",
            "startOffset": 24313,
            "title": "Results"
        },
        {
            "endOffset": 16322,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 16321,
                    "startOffset": 16317
                }
            },
            "secId": "s0005",
            "sentence": "Determining these closely held costs is difficult, and few detailed studies have been published [17].",
            "startOffset": 16221,
            "title": "Introduction"
        },
        {
            "endOffset": 29051,
            "parents": [],
            "secId": "s0055",
            "sentence": "This analysis has several limitations.",
            "startOffset": 29013,
            "title": "Limitations"
        },
        {
            "endOffset": 18704,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 18650,
                    "startOffset": 18643
                },
                "b0090": {
                    "endOffset": 18650,
                    "startOffset": 18643
                }
            },
            "secId": "s0015",
            "sentence": "Following accepted accounting and economic evaluation practices [17,18], equipment constitutes about one-third of total cost.",
            "startOffset": 18579,
            "title": "Annualized capital costs"
        },
        {
            "endOffset": 15620,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 15619,
                    "startOffset": 15615
                }
            },
            "secId": "s0005",
            "sentence": "Chief among these factors is the price of the vaccines [14].",
            "startOffset": 15560,
            "title": "Introduction"
        },
        {
            "endOffset": 26724,
            "parents": [],
            "secId": "s0050",
            "sentence": "Outside its contract to Gavi, GSK has the most to gain by competing on price against Merck for market share.",
            "startOffset": 26616,
            "title": "Discussion"
        },
        {
            "endOffset": 30926,
            "parents": [],
            "secId": "s0070",
            "sentence": "MSF staff commented on drafts of the final report but did not participate in the study design or analysis.",
            "startOffset": 30820,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 30794,
            "parents": [],
            "secId": "s0065",
            "sentence": "RNW has received no payments from pharmaceutical companies and declares no conflicts of interest.",
            "startOffset": 30697,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 27979,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 27978,
                    "startOffset": 27974
                }
            },
            "secId": "s0050",
            "sentence": "Agosti and Goldie estimated a decade ago that \u201cwith every 5-year delay in bringing [HPV] vaccination to developing countries, 1.5 million to 2 million more women will die.\u201d [14].",
            "startOffset": 27801,
            "title": "Discussion"
        },
        {
            "endOffset": 28851,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 28850,
                    "startOffset": 28846
                }
            },
            "secId": "s0050",
            "sentence": "As Agosti and Goldie wrote, for lower-income countries, \u201c\u2026per-dose cost may need to be as low as $1 to $2\u2026\u201d [14].",
            "startOffset": 28738,
            "title": "Discussion"
        },
        {
            "endOffset": 17188,
            "parents": [],
            "secId": "s0010",
            "sentence": "We also identified experts in manufacturing through our contacts and authors of pertinent reports, talks or articles.",
            "startOffset": 17071,
            "title": "Methods"
        },
        {
            "endOffset": 24312,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 24311,
                    "startOffset": 24307
                }
            },
            "secId": "s0045",
            "sentence": "Because per unit costs decline as volume increases, the most important factor in reducing vaccine costs is not a technological breakthrough but \u201ca major increase in procurement\u2026\u201d [18].",
            "startOffset": 24128,
            "title": "Results"
        },
        {
            "endOffset": 31398,
            "parents": [],
            "secId": "s0080",
            "sentence": "This study finds that manufacturing costs for the most widely used vaccine against cervical cancer are low.",
            "startOffset": 31291,
            "title": "Possible summary"
        },
        {
            "endOffset": 14721,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 14720,
                    "startOffset": 14717
                }
            },
            "secId": "s0005",
            "sentence": "When administered before sexual activity, these vaccines are 99 percent effective in preventing associated cancers [8].",
            "startOffset": 14602,
            "title": "Introduction"
        },
        {
            "endOffset": 20801,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "For reasons explained in Appendix A, two batches are estimated to yield a set of 3.6 million doses.",
            "startOffset": 20702,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 26257,
            "parents": [],
            "secId": "s0050",
            "sentence": "Ten-dose vials could lower costs further.",
            "startOffset": 26216,
            "title": "Discussion"
        },
        {
            "endOffset": 25526,
            "parents": [],
            "secId": "s0050",
            "sentence": "Manufacturing costs for a second set are about US$0.48\u2013$0.59 per dose.",
            "startOffset": 25456,
            "title": "Discussion"
        },
        {
            "endOffset": 30433,
            "parents": [],
            "secId": "s0065",
            "sentence": "He has received no payments from pharmaceutical companies and declares no conflicts of interest.",
            "startOffset": 30337,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 21626,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "These produce a middle estimate of $2.37 million and a low estimate of $1.78 million for Gardasil-4, and $1.02 million and $0.76 million for Cervarix.",
            "startOffset": 21476,
            "title": "Raw materials"
        },
        {
            "endOffset": 14883,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 14802,
                    "startOffset": 14799
                },
                "b0050": {
                    "endOffset": 14882,
                    "startOffset": 14878
                }
            },
            "secId": "s0005",
            "sentence": "Gardasil-4 also protects against genital warts associated with HPV-6 and -11 [9] and may induce cross-protection against oncogenic serotypes HPV-31 and -45 [10].",
            "startOffset": 14722,
            "title": "Introduction"
        },
        {
            "endOffset": 25841,
            "parents": [],
            "secId": "s0050",
            "sentence": "From 2006 to 2015, Merck took in about US$13.7 billion from sales of Gardasil-4.",
            "startOffset": 25761,
            "title": "Discussion"
        },
        {
            "endOffset": 28564,
            "parents": [],
            "secId": "s0050",
            "sentence": "As producers of global public health goods, they need to be transparent about their costs and negotiate prices accordingly.",
            "startOffset": 28441,
            "title": "Discussion"
        },
        {
            "endOffset": 27644,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 27536,
                    "startOffset": 27532
                }
            },
            "secId": "s0050",
            "sentence": "Despite being cost-effective in most countries [30], globally the burden of HPV cancers and loss of productivity in the prime of life have hardly been touched.",
            "startOffset": 27485,
            "title": "Discussion"
        },
        {
            "endOffset": 21860,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 21859,
                    "startOffset": 21855
                }
            },
            "secId": "s0030",
            "sentence": "Based on in-depth studies of other vaccines and specific reports for Gardasil-4 and Cervarix, it appears that both Merck and GSK have approximately 152 personnel involved in manufacturing their vaccines [21].",
            "startOffset": 21652,
            "title": "Manufacturing personnel"
        },
        {
            "endOffset": 21231,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For Gardasil-4, this analysis estimates that the retail costs for all material to manufacture a set of 15.4 million doses are approximately $2.9 million.",
            "startOffset": 21078,
            "title": "Raw materials"
        },
        {
            "endOffset": 31060,
            "parents": [],
            "secId": "s0070",
            "sentence": "MSF interns researched the sales, volume, and profit figures in Appendix B.",
            "startOffset": 30985,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 26010,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 26009,
                    "startOffset": 26002
                },
                "b0120": {
                    "endOffset": 26009,
                    "startOffset": 26002
                }
            },
            "secId": "s0050",
            "sentence": "Its gross profits more than match any reasonable estimate of past corporate research and development costs incurred for this vaccine, net of taxpayer subsidies [23,24].",
            "startOffset": 25842,
            "title": "Discussion"
        },
        {
            "endOffset": 13476,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 13475,
                    "startOffset": 13470
                },
                "b0010": {
                    "endOffset": 13475,
                    "startOffset": 13470
                }
            },
            "secId": "s0005",
            "sentence": "Approximately 85% of these new cases and over 90% of the 270,000 deaths from cervical cancer occur in lower- and middle-income countries, where cervical cancer remains a leading cause of death [1,2].",
            "startOffset": 13277,
            "title": "Introduction"
        },
        {
            "endOffset": 26389,
            "parents": [],
            "secId": "s0050",
            "sentence": "The estimated manufacturing costs of Cervarix for the first set lie between US$6.16 and $9.39 which is well above the price to Gavi.",
            "startOffset": 26257,
            "title": "Discussion"
        },
        {
            "endOffset": 16603,
            "parents": [],
            "secId": "s0005",
            "sentence": "It provides important insights into global price barriers and a useful framework for research and decisions concerning accessible pricing.",
            "startOffset": 16465,
            "title": "Introduction"
        },
        {
            "endOffset": 26615,
            "parents": [],
            "secId": "s0050",
            "sentence": "Its gross profits of $2.6 billion more than covered its past, net corporate costs for research and development.",
            "startOffset": 26504,
            "title": "Discussion"
        },
        {
            "endOffset": 30336,
            "parents": [],
            "secId": "s0065",
            "sentence": "He received none of this money, but some of it went to general support for his regular salary.",
            "startOffset": 30242,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 15013,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 15012,
                    "startOffset": 15008
                }
            },
            "secId": "s0005",
            "sentence": "In 2009, the World Health Organization (WHO) recommended both HPV vaccines for girls aged 9\u201313, which Gavi promptly adopted [11].",
            "startOffset": 14884,
            "title": "Introduction"
        },
        {
            "endOffset": 22069,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Staff for manufacturing, quality assurance, and quality control (QA-QC) to GMP standards, filling & packaging, and supervision are included in these estimates and reflect industry and independent information.",
            "startOffset": 21861,
            "title": "Manufacturing personnel"
        },
        {
            "endOffset": 29529,
            "parents": [],
            "secId": "s0055",
            "sentence": "The high, middle, and low ranges are estimates, and actual costs will depend on the details of each variable in our estimates, such as the manufacturing site, details of manufacturing, the costs of GMP, the number and costs of personnel needed to make each vaccine, and fluctuations in costs of raw materials.",
            "startOffset": 29220,
            "title": "Limitations"
        },
        {
            "endOffset": 24037,
            "parents": [],
            "secId": "s0045",
            "sentence": "Because filling and packaging constitute 58.2% of total costs in the second set, manufacturing the vaccine in ten-dose vials would lower the cost per dose to around $0.21 a dose, or $0.42 for a two-dose course per person (Table 2).",
            "startOffset": 23806,
            "title": "Results"
        },
        {
            "endOffset": 16464,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study presents the first detailed cost estimate of the complex manufacturing process of new-generation vaccines Gardasil-4 and Cervarix.",
            "startOffset": 16323,
            "title": "Introduction"
        },
        {
            "endOffset": 22659,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 22554,
                    "startOffset": 22547
                },
                "b0090": {
                    "endOffset": 22554,
                    "startOffset": 22547
                }
            },
            "secId": "s0035",
            "sentence": "Based on other studies of manufacturing cost [17,18], factory and administrative overhead costs equal 45 percent of the cost of both raw materials and labor.",
            "startOffset": 22502,
            "title": "Factory and administrative overheads"
        },
        {
            "endOffset": 23275,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The fill/pack staff are included in personnel, and indirect costs are part of overheads.",
            "startOffset": 23187,
            "title": "Filling and packaging"
        },
        {
            "endOffset": 20614,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "For reasons explained in Appendix A, a \u201cset\u201d is estimated to yield 15.4 million doses.",
            "startOffset": 20528,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 30241,
            "parents": [],
            "secId": "s0065",
            "sentence": "Over the period of 2013\u20132015, DWL\u2019s department received $28,200 from MSF based on a research contract to carry out this research.",
            "startOffset": 30112,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 20527,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "These 6 batches are called a set.",
            "startOffset": 20494,
            "title": "Vaccine yield"
        },
        {
            "endOffset": 18040,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 18039,
                    "startOffset": 18035
                }
            },
            "secId": "s0010",
            "sentence": "In particular, R&D to discover and develop a drug or vaccine are widely regarded as sunk costs and not part of manufacturing costs, as the President of Merck Vaccines, experts cited here, and the UNIDO Manual over its many editions state [20].",
            "startOffset": 17797,
            "title": "Methods"
        },
        {
            "endOffset": 21077,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Actual costs vary by brand and bulk-order discounts.",
            "startOffset": 21025,
            "title": "Raw materials"
        },
        {
            "endOffset": 30091,
            "parents": [],
            "secId": "s0060",
            "sentence": "RW was involved in the cost calculations, revisions, and served as a senior economic advisor.",
            "startOffset": 29998,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 13276,
            "parents": [],
            "secId": "s0005",
            "sentence": "Cervical cancer is the second most common cancer in females, with over 500,000 new cases per year worldwide.",
            "startOffset": 13168,
            "title": "Introduction"
        },
        {
            "endOffset": 22319,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "(Compensation in France differs from the U.S. See Appendix A.)",
            "startOffset": 22257,
            "title": "Manufacturing personnel"
        },
        {
            "endOffset": 26215,
            "parents": [],
            "secId": "s0050",
            "sentence": "Since 2010, Merck\u2019s sales have steadily risen to more than 21 million doses in 2015; so the manufacturing costs for the second set sold to Gavi and developing countries range between $0.48\u2013$0.59 per dose.",
            "startOffset": 26011,
            "title": "Discussion"
        },
        {
            "endOffset": 15125,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 15124,
                    "startOffset": 15120
                }
            },
            "secId": "s0005",
            "sentence": "As of 2015, WHO now recommends two doses of these vaccines, spaced 6\u201312 months apart, for girls aged 9\u201313 [12].",
            "startOffset": 15014,
            "title": "Introduction"
        },
        {
            "endOffset": 15437,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15436,
                    "startOffset": 15433
                }
            },
            "secId": "s0005",
            "sentence": "The lowest known prices outside Gavi are US$12.83 for Gardasil-4 in Brazil and $12.87 for Cervarix in South Africa [2].",
            "startOffset": 15318,
            "title": "Introduction"
        },
        {
            "endOffset": 21024,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Based on information made public by Merck and GSK or other sources, we researched in detail the materials, quantities, costs, and patterns of use or reuse needed to manufacture each vaccine (See Appendix A).",
            "startOffset": 20817,
            "title": "Raw materials"
        },
        {
            "endOffset": 30984,
            "parents": [],
            "secId": "s0070",
            "sentence": "They suggested names of experts in vaccine manufacturing.",
            "startOffset": 30927,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 24480,
            "parents": [],
            "secId": "s0045",
            "sentence": "As shown in Appendix B (worldwide sales and profits), Merck\u2019s sales have steadily risen since 2010 to more than 21 million doses a year.",
            "startOffset": 24344,
            "title": "Results"
        },
        {
            "endOffset": 25602,
            "parents": [],
            "secId": "s0050",
            "sentence": "These estimates are well below the price of US$4.50 given to Gavi by Merck.",
            "startOffset": 25527,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X16308568",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "csclendi@gmail.com",
                "first": "Chaevia",
                "initial": "C.",
                "last": "Clendinen"
            },
            {
                "email": "yapei.zhang@yale.edu",
                "first": "Yapei",
                "initial": "Y.",
                "last": "Zhang"
            },
            {
                "email": "rnwarbur@uvic.ca",
                "first": "Rebecca N.",
                "initial": "R.N.",
                "last": "Warburton"
            },
            {
                "email": "lightdo@rowan.edu",
                "first": "Donald W.",
                "initial": "D.W.",
                "last": "Light"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.09.042",
        "firstpage": "5984",
        "issn": "0264410X",
        "keywords": [
            "Access",
            "Affordability",
            "Gavi",
            "Human papillomavirus",
            "Manufacturing cost",
            "Vaccine"
        ],
        "lastpage": "5989",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Manufacturing costs of HPV vaccines for developing countries"
    }
}